These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 35957721)
1. Survival impact of additional induction chemotherapy in nasopharyngeal carcinoma with chronic hepatitis B infection: a retrospective, bi-center study. Li H; Chen M; Li S; Luo C; Qiu X; Ruan G; Mao Y; Zhang G; Liu L Ann Transl Med; 2022 Jul; 10(13):731. PubMed ID: 35957721 [TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538 [TBL] [Abstract][Full Text] [Related]
3. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis. Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056 [TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966 [TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis. Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182 [TBL] [Abstract][Full Text] [Related]
6. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study. Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950 [TBL] [Abstract][Full Text] [Related]
7. Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II-IVb Nasopharyngeal Carcinoma. Liu SL; Sun XS; Lu ZJ; Chen QY; Lin HX; Tang LQ; Bei JX; Guo L; Mai HQ Front Oncol; 2020; 10():539321. PubMed ID: 33240805 [TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410 [TBL] [Abstract][Full Text] [Related]
9. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial. Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190 [TBL] [Abstract][Full Text] [Related]
10. Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma. Wang YW; Ho SY; Lee SW; Chen CC; Litsu S; Huang WT; Yang CC; Lin CH; Chen HY; Lin LC Int J Med Sci; 2020; 17(5):568-576. PubMed ID: 32210706 [No Abstract] [Full Text] [Related]
11. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study. Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907 [TBL] [Abstract][Full Text] [Related]
12. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study. Li SW; Wang H; Liu ML; Zhang HB; Xiang YQ; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X Med Oncol; 2013 Mar; 30(1):322. PubMed ID: 23254962 [TBL] [Abstract][Full Text] [Related]
13. Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis. Lai L; Chen X; Zhang C; Chen X; Chen L; Tian G; Zhu X Front Oncol; 2020; 10():610787. PubMed ID: 33665166 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of concurrent chemoradiotherapy with induction chemotherapy Liu Y; Yang L; Zhang S; Lin B Transl Cancer Res; 2022 May; 11(5):1207-1218. PubMed ID: 35706809 [TBL] [Abstract][Full Text] [Related]
15. Explore the Value of Adding Induction Chemotherapy to Concurrent Chemoradiotherapy in T3-4N0M0 Nasopharyngeal Carcinoma Patients: A Retrospective Study. Li P; Zhang Q; Luo D; Jiang F; Jin Q; Hua Y; Jin T; Chen X Cancer Manag Res; 2021; 13():7067-7076. PubMed ID: 34526821 [TBL] [Abstract][Full Text] [Related]
16. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma. Wang C; Tang X; Wang J; Song J; Xu Y Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781 [TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Wei Z; Zhang Z; Luo J; Li N; Peng X J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162 [TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis. He Y; Zhao Z; Wang Y; He J; Chai J; Wei Z; Guan H; Wang J; Liu Z; Li R; Mu X; He L; Peng X Clin Otolaryngol; 2021 Sep; 46(5):976-982. PubMed ID: 33821552 [TBL] [Abstract][Full Text] [Related]
19. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA. Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Concurrent Chemoradiotherapy Combined With Induction Chemotherapy or Adjuvant Chemotherapy in Patients With Stage II-IVA Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis and Meta-Analysis. Yang J; Liang ZG; Jiang YT; Chen KH; Li L; Qu S; Zhu XD Front Oncol; 2021; 11():778836. PubMed ID: 34926289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]